CEO and co-founder of Hummingbird Bioscience
Seeing the exciting progress in systems biology and immunology over the past decade, Dr Piers Ingram co-founded Hummingbird in 2015 in order to apply these advances to novel drug discovery and development.
In just five years, Hummingbird has successfully produced promising, novel drug candidates, with its leading programmes entering the clinic. Hummingbird is leading the pack alongside biopharma giants with a powerful approach of finding new drugs for diseases that are resistant to conventional treatment.
Prior to Hummingbird, Piers had spent 15 years in the biopharmaceutical industry across various disciplines from academic research to R&D consulting and commercial strategy. After his undergraduate studies in Applied Mathematics, Piers completed a PhD in Systems Biology at Imperial College London, supported by the Wellcome Trust.
